
|Videos|October 30, 2013
Other Targets in Ovarian Cancer
Author(s)Michael Birrer, MD, PhD
Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.
Advertisement
Clinical Pearls
Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.
- There is an ongoing debate concerning the ideal use and efficacy of antiangiogenic agents outside of bevacizumab
- The folate receptor is a validated target in ovarian cancer
- Ovarian cancer has not been as well characterized and developed in the immunotherapy space compared to melanoma or renal cell carcinoma
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































